Sophia Genetics (FRA:90B) Long-Term Debt: €41.39 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:90B Sophia Genetics SA FRA:90B
73 GF Score
Price €5.00
GF Value €4.32
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Sophia Genetics Long-Term Debt?

Sophia Genetics FRA:90B +0.81% 73 Long-Term Debt is €41.39 Mil as of Mar. 2026. GuruFocus rates FRA:90B with a GF Score™ of 73/100 and a GF Value™ of €4.32 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Sophia Genetics's Long-Term Debt for the quarter that ended in Mar. 2026 was €41.39 Mil.

Sophia Genetics's quarterly Long-Term Debt increased from Sep. 2025 (€40.54 Mil) to Dec. 2025 (€40.76 Mil) and increased from Dec. 2025 (€40.76 Mil) to Mar. 2026 (€41.39 Mil).

Sophia Genetics's annual Long-Term Debt increased from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€12.64 Mil) and increased from Dec. 2024 (€12.64 Mil) to Dec. 2025 (€40.76 Mil).

Sophia Genetics  (FRA:90B) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Sophia Genetics Long-Term Debt Related Terms

Sophia Genetics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Sophia Genetics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sophia Genetics Long-Term Debt Chart

Sophia Genetics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 12.64 40.76

Sophia Genetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.32 41.15 40.54 40.76 41.39
FRA:90B
73GF Score
Sophia Genetics SA FRA:90B
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €41.39 Mil mean?
Sophia Genetics (FRA:90B) has a Long-Term Debt of €41.39 Mil as of Mar. 2026.
Is Sophia Genetics' Long-Term Debt too high?
Sophia Genetics' current Long-Term Debt is €41.39 Mil. Overall, Sophia Genetics has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sophia Genetics' Long-Term Debt compare to WEAV and NRC?
Sophia Genetics' Long-Term Debt of €41.39 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Healthcare Providers & Services company?
A good Long-Term Debt depends on the Healthcare Providers & Services industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Sophia Genetics's current Long-Term Debt is €41.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sophia Genetics stock overvalued right now?
Based on GuruFocus' analysis, Sophia Genetics (FRA:90B) is currently considered Modestly Overvalued. The stock's GF Value™ is €4.32, compared to a current price of €5.00 — trading 15.7% above its estimated fair value. The current Long-Term Debt is €41.39 Mil. Sophia Genetics' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Sophia Genetics (FRA:90B), the current Long-Term Debt is €41.39 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sophia Genetics (FRA:90B) Overvalued in 2026?

Based on GuruFocus' analysis, Sophia Genetics stock appears to be overvalued. The current stock price of €5.00 is trading 15.7% above its estimated GF Value™ of €4.32. GuruFocus considers Sophia Genetics to be Modestly Overvalued.

Key valuation signals for FRA:90B:

  • Long-Term Debt: €41.39 Mil
  • GF Value™: €4.32 vs. price of €5.00 (15.7% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the FRA:90B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sophia Genetics Business Description

Other Exchanges SOPH:USA90B:Germany
Address La Piece 12, Rolle, CHE, CH-1180
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
73GF Score

Get the complete analysis for FRA:90B

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.00
Price
€4.32
GF Value